Cell viability assay demonstrated that these primary Rb-deficient meningioma cell lines were resistant to treatment with selective CDK4/6 inhibitors abemaciclib and palbociclib at escalating doses (Fig. 5q). The gene discussed is RB1; the disease is meningioma.